CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

UCB is dedicated to supporting STEM education in the communities where we work and live. As part of this commitment, UCB is a proud sponsor of the new special exhibit, “The Secret World Inside You,” at Atlanta’s Fernbank Museum of Natural History.

UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018).

Last year, UCB was invited to become a member of the Association of Military Surgeons of the United States (AMSUS) Executive Advisory Board as the only pharmaceutical industry representative.

Ben Morrison—comedian and Crohn’s Advocate—speaks candidly about his experience living with Crohn’s disease. He shares personal insights on the progress of Crohn’s care and the availability of information over the last 20 years.

It’s that time of the year again. Open enrollment for insurance has closed, and it is time to start using your new 2018 plans. Sometimes, understanding your health coverage and planning for your healthcare needs can be challenging.

Following a recent review of Tussionex^® (hydrocodone polistirex and chlorpheniramine polistirex) – a cough syrup containing hydrocodone and chlorpheniramine– we determined the benefit-risk balance for the use of Tussionex^® to treat cough associated with cold or allergy in children was no longer favorable. Because of this, UCB proactively approached the U.S. Food and Drug Administration (FDA) to request that Tussionex^® be limited to use in adults.